1. Home
  2. BPMC vs STVN Comparison

BPMC vs STVN Comparison

Compare BPMC & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • STVN
  • Stock Information
  • Founded
  • BPMC 2008
  • STVN 1949
  • Country
  • BPMC United States
  • STVN Italy
  • Employees
  • BPMC N/A
  • STVN N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • STVN Containers/Packaging
  • Sector
  • BPMC Health Care
  • STVN Consumer Discretionary
  • Exchange
  • BPMC Nasdaq
  • STVN Nasdaq
  • Market Cap
  • BPMC 5.8B
  • STVN 5.7B
  • IPO Year
  • BPMC 2015
  • STVN 2021
  • Fundamental
  • Price
  • BPMC $97.17
  • STVN $24.05
  • Analyst Decision
  • BPMC Buy
  • STVN Buy
  • Analyst Count
  • BPMC 21
  • STVN 6
  • Target Price
  • BPMC $124.05
  • STVN $25.08
  • AVG Volume (30 Days)
  • BPMC 973.2K
  • STVN 305.4K
  • Earning Date
  • BPMC 05-01-2025
  • STVN 05-08-2025
  • Dividend Yield
  • BPMC N/A
  • STVN 0.25%
  • EPS Growth
  • BPMC N/A
  • STVN N/A
  • EPS
  • BPMC N/A
  • STVN 0.50
  • Revenue
  • BPMC $562,121,000.00
  • STVN $1,215,559,879.00
  • Revenue This Year
  • BPMC $44.85
  • STVN $8.42
  • Revenue Next Year
  • BPMC $32.06
  • STVN $10.36
  • P/E Ratio
  • BPMC N/A
  • STVN $47.26
  • Revenue Growth
  • BPMC 99.19
  • STVN 3.81
  • 52 Week Low
  • BPMC $73.04
  • STVN $16.56
  • 52 Week High
  • BPMC $121.90
  • STVN $28.77
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 59.54
  • STVN 66.95
  • Support Level
  • BPMC $87.03
  • STVN $20.14
  • Resistance Level
  • BPMC $104.86
  • STVN $22.61
  • Average True Range (ATR)
  • BPMC 3.86
  • STVN 1.10
  • MACD
  • BPMC 1.24
  • STVN 0.18
  • Stochastic Oscillator
  • BPMC 64.38
  • STVN 95.45

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: